RT @OGdukeneurosurg: Autonomic nervous system

RT @PhysInHistory: "If you're not having fun, you're not learning. There's a pleasure in finding things out." - Richard Feynman https://t.…

RT @hamptonism: Machine Learning Algorithms:

My colleagues and I have published a new strategic article in Alzheimer’s & Dementia, the journal of the Alzheimer Association, that discusses how to define meaningful benefits in the next-generation Alzheimer’s disease (AD) clinical care pathway. Our article utilizes the clinical and biological framework of AD, and aims to further integrate and expand the parameters of meaningful benefits towards a precision medicine framework. In this publication, we discuss: (1) the lack of consideration for biomarkers in the current concept of meaningfulness in AD; (2) the lack of gold standards for determining minimal biologically and clinically important differences (MBCIDs) in AD trials; (3) how treatment benefits of disease-modifying treatments are cumulative and increase over time; (4) the different concepts of meaningfulness among key stakeholders. Read more here: @AyaElhage @WileyNeuro #neurology #neuroscience #alzheimersdisease #alzheimer #MCID #PatientReportedOutcomes #biomarker #Dementia #mildcognitiveimpairment #clinicaltrial #clinicaldevelopment #cognitivedecline #outcomesresearch #outcomes #drugdevelopment #trialdesign #biomarkers #precisionmedicine

We are pleased to announce our latest publication in the Journal of Alzheimer's Disease. Depression and circadian rhythm disruptions are non-cognitive neuropsychiatric symptoms (NPS) that can appear at any stage of the Alzheimer’s disease (AD) continuum. Evidence suggests that NPS are linked to AD pathophysiology and hippocampal dysfunction. We examined structural white matter (WM) connectivity and its association with gray matter (GM) atrophy and to identify specific AD-related neural networks linked to NPS in individuals with mild cognitive impairment (MCI). Ninety-six older adult participants were divided into three groups (MCI with and without NPS, and age-matched healthy controls) based on the Global Depression Scale (GDS), Neuropsychiatric Inventory (NPI), Clinical Dementia Rating (CDR), and Mini-Mental Status Examination (MMSE). Voxel-based morphometry (VBM) and tract-based spatial statistics were employed to identify structural and microstructural alterations. Network-based statistics analyzed structural White Matter (WM) connectivity differences between MCI groups and healthy controls. @IOSPress_STM #neurology #psychiatry #neuroscience #brain #brainhealth #dementia #alzheimer #alzheimersdisease #cognitivedecline #MCI #mildcognitiveimpairment #NPS #neuropsychiatricsymptoms #BPSD #neuroimaging #networks #complexnetworks #systemsthinking #systemsneurophysiology #radiology #brainfunction #datascience #voxelbasedmorphology #networkbasedstatistics #NPI #CDR #MMSE #GDS #depression #psychopathology #whitematter #greymatter #cortex #hippocampus #amygdala #limbicsystem #thalamus #putamen #pallidum #brainatrophy #cognition #memory #apathy #anxiety #agitation #delusions #psychosis #sleepwakedisorder

My colleagues and I have published an article in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association where we show that the plasma pTau217 ratio (pTau217R) can predict continuous regional tau accumulation in the brains of amyloid-positive individuals with early Alzheimer’s disease. Read the article here:

Our international neurophysiology research consortium has published a summary of the most recent evidence suggesting a contribution of parvalbumin-positive (PV+) interneuron dysfunction to the #pathophysiology of a spectrum of brain proteinopathies and primary neurodegenerative diseases, such as #Alzheimer's disease, #FrontotemporalDementia (FTD), and #DementiawithLewybodies (DLB). Highlights: • Parvalbumin-positive interneurons regulate cortical excitation/inhibition balance. • Their dysfunction results in cortical hyperexcitability and gamma rhythm disruption. • PV+ interneurons are impaired in AD; their restoration improved patients’ cognition. • Albeit with some differences, PV+ cells are also impaired in FTD and DLB mouse models. • Their dysfunction represents a common pathophysiological aspect across etiologies. @ElsevierConnect @ELSneuroscience @ElsevierNews #neurology #neuroscience #brain #brainhealth #alzheimersdisease #cortex #precisionmedicine #biomarkers Learn more:

My colleagues and I have published a new article in the Cell Press journal MED featuring blood and CSF based fluid biomarkers findings across twelve anti-amyloid-beta clinical trials. The emerging biomarker data provide evidence on the impact of the new therapies on the underlying pathophysiological processes of Alzheimer’s disease, supporting the presence of a disease-modifying effect. Read more here: @SuzanneHendrix @CellPress @oskarhansson #neurology #AlzheimersDisease #alzheimer #biomarkers #clinicaltrials #precisionmedicine #neuroscience #dementia #mildcognitiveimpairment #drugdevelopment #trialdesign #liquidbiopsy #BrainHealth #therapy #outcomes #CSF #alzheimertherapy #ENDALZ #EndAlzheimerNow

My colleagues and I published an article in Alzheimer’s & Dementia exploring if a plasma biomarker, pTau181, can help identify individuals who may experience a faster clinical decline over an 18-month clinical trial. Read it here: #AlzheimersDisease

My colleagues and I have published an article in Alzheimer’s & Dementia on how a blood-based biomarker, ptau217, can predict brain amyloid levels in a broad spectrum of individuals. Read the article #BBM #PET #diagnosis #monitoring #machine-learning #aiml

My colleagues and I wrote an article published in@NatureNeuro on the role of Apolipoprotein E (APOE) in #Alzheimersdisease. Learn more about incorporating APOE genetic testing into clinical practice as we advance towards #precisionmedicine:

Our paper has been published in Nature Neuroscience. Apolipoprotein E in #Alzheimerdisease trajectories and the next-generation clinical care pathway. #genetics #precisionmedicine @NatureNeuro @NaturePortfolio

The EU-US CTAD Task Force identified and published in the Journal of Prevention of #AlzheimerDisease several recommendations and principles that should be considered when evaluating the #meaningfulness of #clinicaltrials . #CognitiveDecline #dementia

We have published a Plain Language Summary on #amyloid-related #imaging abnormalities (ARIA) in Future Medicine. Intended for clinicians who may diagnose and treat #Alzheimersdisease, it offers insightful information on #ARIA. Read more:

The #retina is an emerging #CNS target for potential noninvasive diagnosis and tracking of #Alzheimer's disease (AD). In this new paper, we summarize the evolving evidences, the state-of-the-art and perspectives of AD #pathophysiology in the retina.

Our paper has been published in the Journal of #Alzheimer's Disease. Association of Basal Forebrain Volume with #Amyloid, Tau, and #cognition in #Alzheimersdisease.